You are here: Industry Insights > Cancer

News List

Fast-track pancreatic cancer surgery boosts success, saves money pharmatimes
August 03, 2017
Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
AstraZeneca scores second accelerated FDA review in 2 days for blood cancer drug pharmafile
August 02, 2017
It’s been a rollercoaster week for AstraZeneca. Following the failure of its crucial Mystic trial for its immunotherapy drug Imfinzi, the company has unloaded a string of positive announcements to neutralise potential damage
Breakthrough status for AZ’ lung cancer drug Imfinzi pharmatimes
August 01, 2017
US regulators have granted AstraZeneca’s Imfinzi breakthrough status for the treatment of certain patients with locally-advanced, unresectable non-small cell lung cancer
AZ’s Imfinzi scores FDA breakthrough therapy designation in wake of major trial failure pharmafile
August 01, 2017
Still reeling from the public reaction to the flop of its key Mystic trial, where its injectable immunotherapy drug Imfinzi (durvalumab) failed to show any clinically relevant efficacy in stopping lung cancer progression,
Imfinzi wins breakthrough therapy designation europeanpharmaceuticalreview
August 01, 2017
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer…
CRUK brings commercialisation arm in-house pharmatimes
July 31, 2017
Cancer Research UK has brought its commercialisation arm, Cancer Research Technology (CRT), together with its research funding teams to form a new in-house division called Research and Innovation.
Shooting for the moon: The National Cancer Institute’s Formulary pharmafile
July 31, 2017
Pharmafile spoke to National Cancer Institute's (NCI) Jason Christofaro and Sherry Ansher regarding the development of an agent formulary and its role as part of the wider Moonshot Initiative.
Sandoz to improve treatment access to children with cancer in four developing nations pharmaceutical-technology
July 31, 2017
Novartis Group division Sandoz has expanded its partnership with UK-based charity World Child Cancer to improve access to treatment, as well as optimise survival outcomes for children suffering from cancer in four developing nations.
AZ, Merck link to develop and commercialise cancer drugs pharmatimes
July 28, 2017
AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
EU OKs first-line use of AZ’ Faslodex pharmatimes
July 28, 2017
EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page